Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Clinical trial NCT03646617 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03646617
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-27
- Primary completion
- 2026-03-21
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.